Salarius Pharmaceuticals Inc (SLRX) Stock Price, Quote & News

Company Profile

Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The...

Industry: Biotechnology

Sector: Healthcare

Phone: (713) 913-5608

Website: www.salariuspharma.com

Address:

2450 Holcombe Blvd., Suite X, Houston, United States

98till Nov. 14 at 11:16 PM

$SLRX ask and you shall receive

0 · Reply

d_risk Nov. 14 at 11:14 PM

$SLRX - Salarius Pharmaceuticals, Inc. - 10Q - Updated Risk Factors SLRX warns of potential Nasdaq delisting, ongoing losses with no product revenue, heavy reliance on unproven preclinical candidates, intense competition, regulatory and IP hurdles, operational risks, and uncertainty from political and market shifts. #Biotechnology #PreclinicalDevelopment #MarketVolatility #RegulatoryRisk #Pharmaceuticals 🟢 Added 🟠 Removed https://d-risk.ai/SLRX/10-Q/2025-11-14

0 · Reply

Sowalwindows Nov. 14 at 11:02 PM

$SLRX

0 · Reply

UpWeGo11 Nov. 14 at 10:28 PM

$SLRX

1 · Reply

Gated_Lambo Nov. 14 at 9:49 PM

$SLRX

0 · Reply

1AMBITIOUSSAVAGE Nov. 14 at 9:39 PM

$SLRX waiting for the weak to sell! IM HOLDING… IF NOT ILL BUY YOUR SHARES! THE NEW CBO USED TO WORK FOR MERCK WHICH PURSUES COMPANIES LIKE SLRX CDTX SPRB EARNINGS NEXT WEEK WILL ELEVATE PRICE !!! 🔋 WERE NEXT

0 · Reply